Gene, Genetic Disease, Genotype and Scientist

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Gene

Genetic Disease

Genotype

Scientist

BridgeBio Pharma’s Nulibry Approved as First Treatment for Molybdenum Cofactor Deficiency Type A

XTalks

MARCH 3, 2021

BridgeBio is dedicated to developing therapies for genetic diseases with unmet needs. The FDA remains committed to facilitating the development and approval of safe and effective therapies for patients affected by rare diseases — an area of critical need.”. The approval was granted to BridgeBio Pharma, Inc.

FDA Approval

FDA Approval Genotype Clinical Trials Clinical Trials

Rare Disease Diagnosis: Why Tackling the Genomic Analysis Bottleneck is Key to Advancing Precision Medicine

XTalks

NOVEMBER 10, 2020

Expeditious and accurate diagnoses are necessary for patients to access healthcare services and treatment options for rare genetic diseases. Increasing the efficiency of case analysis and interpretation is essential to providing timely care for patients with genetic diseases.

Genome

Genome Genomics Medicine Genetic Disease

Clinical Research Informer

BridgeBio Pharma’s Nulibry Approved as First Treatment for Molybdenum Cofactor Deficiency Type A

Rare Disease Diagnosis: Why Tackling the Genomic Analysis Bottleneck is Key to Advancing Precision Medicine

Stay Connected